Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial -

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers | Gastrointestinal disorders | Skin disorders
Summary
RCT (n=230) found that benefit-to-risk profile of sonidegib (200mg), a Hedgehog signalling inhibitor, might offer a new treatment option for patients with advanced basal cell carcinoma, a population that is difficult to treat [20 (36%) of 55 patients achieved objective response].
UKMi comment
A commentary notes that BOLT is a well-designed, multicentre, double-blind, randomised trial. It discusses how well the results compare with those from ERIVANCE, which led to FDA approval of vismodegib, another Hedgehog signalling inhibitor.
Related links: Comment